Stocks · News reference

Armata Pharmaceuticals Announces Journal Of Molecular Biology Publication Detailing Structure Of Ar-KM Bacteriophage Targeting Pseudomonas Aeruginosa, Pathogen Addressed By Its AP-PA02 Program

Sep 3, 2026, 11:10 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 12, 2026, 8:29 PMBenzinga Newsdesk
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share
ARMP
BenzingaAug 12, 2026, 8:14 PMBenzinga Newsdesk
Armata Pharmaceuticals Announces Promotion Of David House To CFO
ARMP
BenzingaJul 20, 2026, 4:45 PMVandana Singh
Why Is Armata Pharma Stock Gaining Monday?
ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.
ARMP